2025-524936-20-00RecruitingPhase 1
A study comparing the new drugs PG511/PG521/PG531 produced by Celon Pharma SA with the drug PG203 in healthy volunteers.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- First submitted
- 1 Apr 2026
- Start date
- 20 Jul 2026
- Lead sponsor
- Celon Pharma S.A.
- EU CT number
- 2025-524936-20-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 68
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BioResearch Group sp. z o.o. | Nadarzyn | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.